These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18697252)

  • 41. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis.
    Waegemans T; Wilsher CR; Danniau A; Ferris SH; Kurz A; Winblad B
    Dement Geriatr Cogn Disord; 2002; 13(4):217-24. PubMed ID: 12006732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury.
    El Sayed I; Zaki A; Fayed AM; Shehata GM; Abdelmonem S
    Neurosurg Rev; 2018 Apr; 41(2):427-438. PubMed ID: 27539610
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The use of the combined drug vinpotropil at early stages of cerebrovascular insufficiency].
    Zakharov VV; Lokshina AB; Stakhovskaia LV; Timerbaeva SL; Lagoda OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(9):76-8. PubMed ID: 18686371
    [No Abstract]   [Full Text] [Related]  

  • 44. [The original novel nootropic and neuroprotective agent noopept].
    Ostrovskaia RU; Gudasheva TA; Voronina TA; Seredenin SB
    Eksp Klin Farmakol; 2002; 65(5):66-72. PubMed ID: 12596521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Use of omaron in patients with post-stroke cognitive disorders].
    Parfenov VA; Belavina GR; Vakhnina NV; Gusev VV; Levin IaI; Markin SP; Starchina IuA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(6):41-5. PubMed ID: 19672226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Piracetam in combined pathogenetic therapy of recurrent duodenal ulcer].
    Tsimmerman IaS; Shchetkin DI
    Klin Med (Mosk); 2002; 80(1):48-53. PubMed ID: 11855320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of rivastigmine on cognitive function in patients with traumatic brain injury.
    Silver JM; Koumaras B; Chen M; Mirski D; Potkin SG; Reyes P; Warden D; Harvey PD; Arciniegas D; Katz DI; Gunay I
    Neurology; 2006 Sep; 67(5):748-55. PubMed ID: 16966534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin].
    Vereshchagin NV; Suslina ZA; Timerbaeva SL; Kashina EM; Gnezditskiĭ VV; Maksimova MIu; Rebrova OIu; Smirnova IN
    Ter Arkh; 2001; 73(4):22-7. PubMed ID: 11494441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The effect of piracetam on involuntary movements in Huntington's disease. A double-blind, placebo-controlled study].
    Mateo D; Giménez-Roldán S
    Neurologia; 1996 Jan; 11(1):16-9. PubMed ID: 8714171
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Alzheimer's disease therapy--theory and practice].
    Gabryelewicz T; Barcikowska M; Jarczewska DL
    Wiad Lek; 2005; 58(9-10):528-35. PubMed ID: 16529064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke.
    Derev'yannykh EA; Bel'skaya GN; Knoll EA; Krylova LG; Popov DV
    Neurosci Behav Physiol; 2008 Oct; 38(8):873-5. PubMed ID: 18802768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of akatinol memantine in moderate cognitive impairments.
    Levin OS; Yunishchenko NA; Dudarova MA
    Neurosci Behav Physiol; 2010 Oct; 40(8):926-33. PubMed ID: 20683775
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Piracetam treatment in ischemic stroke].
    Tomczykiewicz K; Domzał T
    Neurol Neurochir Pol; 1997; 31(6):1101-9. PubMed ID: 9591298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Vascular cognitive impairment in young patients].
    Dolgova IN; Starodubtsev AI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(10):14-6. PubMed ID: 21510448
    [No Abstract]   [Full Text] [Related]  

  • 55. Piracetam improves visuomotor and cognitive deficits in early Parkinsonism--a pilot study.
    Oepen G; Eisele K; Thoden U; Birg W
    Pharmacopsychiatry; 1985 Nov; 18(6):343-6. PubMed ID: 4089014
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of piracetam on cognitive performance in patients undergoing bypass surgery.
    Uebelhack R; Vohs K; Zytowski M; Schewe HJ; Koch C; Konertz W
    Pharmacopsychiatry; 2003 May; 36(3):89-93. PubMed ID: 12806565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinicoimmunological effects of piracetam and aevit in the course of duodenal ulcer patients' therapy].
    Balobanov VI; Vakhrushev SP; Velikosel'skaia LM
    Klin Med (Mosk); 1996; 74(7):56-7. PubMed ID: 8992120
    [No Abstract]   [Full Text] [Related]  

  • 58. Cholinomimetic agents and neurocognitive impairment following head injury: a systematic review.
    Poole NA; Agrawal N
    Brain Inj; 2008 Jul; 22(7-8):519-34. PubMed ID: 18568705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Piracetam in the treatment of acute stroke.
    Orgogozo JM
    Pharmacopsychiatry; 1999 Mar; 32 Suppl 1():25-32. PubMed ID: 10338105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical observations concerning piracetam treatment of patients after craniocerebral injury].
    Gościński I; Moskała M; Cichoński J; Polak J; Krupa M; Sliwonik S; Sondej T
    Przegl Lek; 1999; 56(2):119-20. PubMed ID: 10375942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.